New plant will focus on producing Humira.
Abbott just opened a new biologics manufacturing facility in Puerto Rico to support the long-term supply of its leading biologic agent, Humira (adalimumab), and other future biologics. The new facility, Abbott Biotechnology Limited (ABL), received U.S. FDA approval in February to commercially produce Humira for the U.S. market.
“This new facility is a key milestone for Abbott as we move to focus our resources and future growth on biologic and potent-drug manufacturing,” said Lawrence Kraus, vp of manufacturing, global pharmaceutical operations, Abbott. “The advanced, high-quality infrastructure of ABL can meet the exceptionally challenging and stringent processes of biologic manufacturing. With this facility, we can supply Humira to the growing number of patients who have come to rely on this product.”
ABL is now the main production facility for Humira. This plant has significantly more production capacity than the other manufacturing facility for Humira, the Abbott Bioresearch Center (ABC) in Worcester, MA, according to the company The ABC site will now serve as a supporting production facility for Humira and will focus on Abbott’s growing biologics research and development portfolio.
The new plant is Abbott’s single-largest capital investment to date, costing approximately $450 million. With this investment, Abbott can achieve large-scale production volumes in biologic manufacturing, it reports. In addition to producing Humira, the 330,000-sq-ft facility is designed for large-scale production of future products in Abbott’s pipeline that will require advanced manufacturing technologies.